Dr. Thomas Patterson, chief of Division of Infectious Diseases and principal investigator of a San Antonio study site for the new COVID-19 anti-viral drug remdesivir, explains how the early results of the study are promising.
Newsroom
Dr. Thomas Patterson, chief of Division of Infectious Diseases and principal investigator of a San Antonio study site for the new COVID-19 anti-viral drug remdesivir, explains how the early results of the study are promising.